VEA
ADPT icon

Virtus ETF Advisers’s Adaptive Biotechnologies ADPT Stock Holding History

Virtus ETF Advisers’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$347K Buy
+16,197
New +$248K 0.13% 194

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Virtus ETF Advisers's ADPT Position: Q2 2026 in Review

Virtus ETF Advisers opened a new position in Adaptive Biotechnologies (ADPT) in Q2 2026: 16,197 shares worth $347K. The stake represents 0.13% of the portfolio and ranks #194 among its holdings.

300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Virtus ETF Advisers held 16,197 shares of Adaptive Biotechnologies worth $347K as of Q2 2026.
  • Adaptive Biotechnologies was a new Virtus ETF Advisers position in Q2 2026.
  • Adaptive Biotechnologies made up 0.13% of Virtus ETF Advisers's portfolio in Q2 2026, its #194 holding.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Virtus ETF Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.